 Etoposide
"Etoposide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
| Descriptor ID |
D005047
|
| MeSH Number(s) |
D02.455.426.559.847.638.960.675.250 D04.615.638.960.675.250 D09.408.348.275
|
| Concept/Terms |
Etoposide- Etoposide
- Eposide
- Demethyl Epipodophyllotoxin Ethylidine Glucoside
Etopos- Etopos
- Lemery Brand of Etoposide
Exitop- Exitop
- Baxter Oncology Brand of Etoposide
Lastet- Lastet
- Sanfer Brand of Etoposide
- Prasfarma Brand of Etoposide
Onkoposid- Onkoposid
- Onkoworks Brand of Etoposide
Riboposid- Riboposid
- ribosepharm Brand of Etoposide
Toposar- Toposar
- Teva Brand of Etoposide
- Etoposide Teva
Vepesid- Vepesid
- Bristol-Myers Squibb Brand of Etoposide
- Bristol Myers Squibb Brand of Etoposide
- Bristol-Myers Brand of Etoposide
- Bristol Myers Brand of Etoposide
Celltop- Celltop
- Baxter Brand of Etoposide
Eposin- Eposin
- Tedec Meiji Brand of Etoposide
- Pharmachemie Brand of Etoposide
- Etomedac
- Medac Brand of Etoposide
Eto-GRY- Eto-GRY
- Eto GRY
- Gry Brand of Etoposide
|
Below are MeSH descriptors whose meaning is more general than "Etoposide".
Below are MeSH descriptors whose meaning is more specific than "Etoposide".
This graph shows the total number of publications written about "Etoposide" by people in this website by year, and whether "Etoposide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1985 | 0 | 1 | 1 | | 1986 | 0 | 2 | 2 | | 1987 | 1 | 0 | 1 | | 1988 | 0 | 3 | 3 | | 1989 | 1 | 0 | 1 | | 1990 | 0 | 1 | 1 | | 1991 | 1 | 1 | 2 | | 1992 | 0 | 2 | 2 | | 1993 | 0 | 2 | 2 | | 1994 | 0 | 3 | 3 | | 1995 | 1 | 1 | 2 | | 1996 | 0 | 3 | 3 | | 1997 | 0 | 2 | 2 | | 1998 | 0 | 1 | 1 | | 2000 | 1 | 2 | 3 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 2 | 2 | | 2005 | 0 | 2 | 2 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2009 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2015 | 0 | 3 | 3 | | 2017 | 0 | 2 | 2 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Etoposide" by people in Profiles.
-
Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, Smith SM. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
-
Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. J Clin Oncol. 2017 Jul 10; 35(20):2260-2267.
-
Shaikh F, Cullen JW, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Villaluna D, Krailo M, Billmire DF, Rescorla FJ, Egler RA, Dicken BJ, Ross JH, Schlatter M, Rodriguez-Galindo C, Frazier AL. Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children's Oncology Group. J Clin Oncol. 2017 Apr 10; 35(11):1203-1210.
-
Dandekar VK, Young J, Kiel K, Bonomi P, Fidler MJ, Batus M, Sher DJ. Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. Am J Clin Oncol. 2015 Dec; 38(6):605-9.
-
Noujaim J, Thway K, Jones RL, Miah A, Khabra K, Langer R, Kasper B, Judson I, Benson C, Kollàr A. Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study. Anticancer Res. 2015 Nov; 35(11):6213-7.
-
Gallo K, Brickman A, Warren WH, Gattuso P, Seder CW. Unresectable Middle Mediastinal Biphasic Pulmonary Blastoma. Anticancer Res. 2015 Nov; 35(11):6325-7.
-
Chalmers AW, Katz DA, Miller IJ, Gregory SA. Successful treatment of hepatosplenic T-cell lymphoma with ESHAP followed by autologous stem cell transplant. Clin Adv Hematol Oncol. 2013 Feb; 11(2):109-13.
-
Gielda BT, Marsh JC, Zusag TW, Faber LP, Liptay M, Basu S, Warren WH, Fidler MJ, Batus M, Abrams RA, Bonomi P. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun; 6(6):1079-86.
-
Milman S, Kim AW, Warren WH, Liptay MJ, Miller C, Basu S, Faber LP. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy. Ann Thorac Surg. 2009 Sep; 88(3):945-50; discussion 950-1.
-
Bleibel WK, Duan S, Huang RS, Kistner EO, Shukla SJ, Wu X, Badner JA, Dolan ME. Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum Genet. 2009 Mar; 125(2):173-80.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|